Drugsoft drug data and web services
|
Drugsoft drug data and web services |
|
|
Hepatox®, a bibliographical database, reviews drug-induced liver injury.
It was created in 1980 by Michel BIOUR (MD, PhD). Then, this database has been monthly updated in accordance with other
bibliographical databases such as Embase® (Elsevier), Medline® or X-Reactions® (Adis Press) and to the analysis of
the references cited in the articles.
The author has re-evaluated all the published cases for selection and classification in accordance with criterions usually
validated in hepatology.
1323 drugs are registered with 17,004 corresponding references. We provide the number of references for each type
of liver disorder and one selected reference for each drug.
This application is available for
Android, for
Iphone and for
Ipad
| 1 | 2 |
|---|---|
| Search for a drug | Get hepatotoxicity profile |
 |
 |
|
Hepatox®: is a bibliographical tool used as a support for: - evaluating the role of drug(s) as a cause of liver injury, - safety, by avoiding to prescribe any drug known to cause any type of liver injury in a patient at risk, - pharmacoepidemiological studies especially for case/no-case type. This specific type of database requires anyway a few safety practices. Actually, three precautions have to be taken by the readers prior using our database: a) a drug which is known for its hepatotoxicity is not always the only cause of a liver injury observed in a patient; b) and vice versa, the liver injury may come from another drug which is not registered in our list; c) the hepatotoxic potential of each drug could be evaluated through the number of references in the index. Nevertheless, this method is strongly inadvisable for drugs marketed in only one country. Liver disorders are classified in accordance with the following definitions: - biological disorders are defined as an asymptomatic rise in AST and ALT ranged from 1,1 to 6 times the upper limit of the normal (xULN), and/or rise in alkaline phosphatases ranged from 1,1 to 1,7 xULN; - acute disorders are defined either as a rise in AST and ALT of more than 6 xULN, and/or rise in alkaline phosphatases of more than 1,7 xULN. The type of pattern of the liver injury was related to the histological examination of the liver, or as a default, through the ratio (R) of the maximum xULN expression rises in aminotransferases and in alkaline phosphatases (R<2: cholestatic; R>5: cytolytic; R ranged from 2 to 5: mixed). - severe disorders are defined as fulminant or subfulminant hepatitis or death or liver injury accompanied by signs of liver failure (encephalopathy, PT<60% or Factor V<60%). - chronic disorders are defined as a persistent rise in liver enzymes during a period of more than six months or as a chronic hepatitis as defined by histology. - the other hepatic disorders are classified in accordance with the histological definitions. List of the terms used in the 'Particularities' section: specific antibodies: - anti-M: anti-Mitochondria - anti-LM: anti-Liver Microsome - anti-LKM: anti-Liver and Kidney Microsome - anti-SM: anti-Smooth Muscle - anti-N: anti-Nuclear miscellaneous: - CR/.: Cross-Reaction with - FNH: Focal Nodular Hyperplasia - RNH: Regenerative Nodular Hyper - I/.: Potentiation in case of combination with - HAI: related to Hepatic Artery Infusion - HCC: Hepatocellular Carcinoma - IMLS: Infectious Mononucleosis Like-Syndrome - OLT : Orthoptic Liver Transplantation - PBC: Primary Biliary Cirrhosis - VOD: Veno-Occlusive-Disease - NA: Not Available |
|